The serum levels of ANXA2 were significantly increased in the patients with HCC (median, 567.2 vs. 241.9 μg/ml; P=0.003) and cirrhosis (median, 414.8 μg/ml vs. 241.9 μg/ml, P=0.011) compared with the healthy controls (Fig. 1). This evidence concerns the gene ANXA2 and hepatocellular carcinoma.